Exelixis, Inc. (NASDAQ:EXEL)‘s stock had its “outperform” rating reissued by analysts at William Blair in a research report issued to clients and investors on Thursday.

EXEL has been the topic of several other reports. Cann restated a “hold” rating on shares of Exelixis in a research report on Wednesday, April 19th. Zacks Investment Research downgraded Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 28th. SunTrust Banks, Inc. began coverage on Exelixis in a research report on Thursday, July 13th. They set a “buy” rating and a $33.00 target price on the stock. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Exelixis in a research report on Friday, April 21st. Finally, TheStreet upgraded Exelixis from a “d” rating to a “c+” rating in a research report on Tuesday, May 2nd. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Exelixis has an average rating of “Buy” and an average target price of $20.95.

Exelixis (NASDAQ:EXEL) traded down 3.25% on Thursday, hitting $27.11. The stock had a trading volume of 3,571,643 shares. The stock’s 50 day moving average is $24.03 and its 200 day moving average is $21.60. The stock has a market cap of $7.93 billion, a price-to-earnings ratio of 1290.95 and a beta of 1.88. Exelixis has a one year low of $8.75 and a one year high of $28.23.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Monday, May 1st. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.06. Exelixis had a return on equity of 126.82% and a net margin of 1.37%. The business had revenue of $80.90 million for the quarter, compared to the consensus estimate of $65.23 million. During the same period in the prior year, the business earned ($0.27) earnings per share. The business’s revenue was up 425.3% on a year-over-year basis. Analysts anticipate that Exelixis will post $0.18 earnings per share for the current year.

WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/27/exelixis-inc-nasdaqexel-rating-reiterated-by-william-blair.html.

In other news, insider Patrick J. Haley sold 5,000 shares of the stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $18.46, for a total value of $92,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael Morrissey sold 259,149 shares of the stock in a transaction dated Friday, May 5th. The shares were sold at an average price of $22.24, for a total value of $5,763,473.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 709,647 shares of company stock valued at $15,673,068. Insiders own 5.10% of the company’s stock.

Large investors have recently modified their holdings of the stock. Fortaleza Asset Management Inc. acquired a new stake in shares of Exelixis during the first quarter worth $106,000. First Quadrant L P CA acquired a new stake in shares of Exelixis during the second quarter worth $144,000. Meeder Asset Management Inc. acquired a new stake in shares of Exelixis during the first quarter worth $170,000. Atlantic Trust Group LLC acquired a new stake in shares of Exelixis during the first quarter worth $216,000. Finally, Klingenstein Fields & Co. LLC acquired a new stake in shares of Exelixis during the first quarter worth $217,000. Hedge funds and other institutional investors own 80.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.